CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals (NASDAQ: MIPI), a biopharmaceutical company specializing in the emerging field of molecular medicine, today announced that it has priced $150 million in bonds due in 2012 with a syndicate of institutional investors. In connection with the transaction, Molecular Insight will issue warrants for the purchase of an aggregate of 6,021,247 shares of common stock. These warrants represent 18 percent dilution of common shares on a fully diluted, post-money basis.
